Iron overload status and univariate outcomes
| Outcome . | Iron overload defined as LIC >1.8 mg/g . | P . | Iron overload defined as LIC >5 mg/g . | P . | ||
|---|---|---|---|---|---|---|
| No iron overload, Prob (95% CI) . | Iron overload, Prob (95% CI) . | No iron overload, Prob (95% CI) . | Iron overload, Prob (95% CI) . | |||
| N | 28 | 60 | 65 | 23 | ||
| Overall survival, 1 y | 82% (62-92) | 72% (58-81) | .33 | 74% (61-83) | 78% (55-90) | .68 |
| NRM, 1 y* | 14% (2%-27%) | 13% (5%-22%) | .86 | 14% (5%-22%) | 13% (0%-26%) | .95 |
| Relapse, 1 y* | 21% (6%-73%) | 23% (13%-34%) | .92 | 22% (9%-36%) | 23% (12%-35%) | .91 |
| Composite end point, 1 y*† | 71% (51%-91%) | 80% (65%-95%) | .44 | 72% (53%-91%) | 81% (55%-97%) | .94 |
| Serious infections, 1 y* | 64% (43%-85%) | 73% (59%-88%) | .35 | 69% (55%-83%) | 74% (51%-97%) | .53 |
| Bacterial infections, 1 y* | 11% (0%-22%) | 13% (5%-22%) | .72 | 12% (4%-20%) | 13% (0%-27%) | .98 |
| Viral infections, 1 y* | 57% (37%-77%) | 68% (54%-83%) | .27 | 63% (49%-77%) | 70% (46%-93%) | .48 |
| Fungal infections, 1 y* | 7% (0%-17%) | 12% (4%-20%) | .49 | 12% (4%-20%) | 4% (0%-12%) | .28 |
| Respiratory failure, 1 y* | 11% (0%-22%) | 18% (9%-27%) | .38 | 17% (8%-26%) | 13% (1%-26%) | .64 |
| Cardiac failure, 1 y* | 0% | 8% (1%-15%) | .13 | 6% (1%-12%) | 9% (0%-20%) | .53 |
| Renal failure, 1 y* | 7% (0%-16%) | 10% (3%-17%) | .66 | 9% (2%-16%) | 9% (0%-20%) | .92 |
| Hepatic VOD, 1 y* | 4% (1%-8%) | 0% | .32 | 2% (0%-5%) | 0% | .74 |
| Acute GVHD, 100 days* | 50% (30%-70%) | 33% (21%-45%) | .16 | 42% (29%-54%) | 30% (12%-49%) | .44 |
| Chronic GVHD, 1 y* | 21% (6%-37%) | 17% (7%-26%) | .72 | 22% (9%-36%) | 15% (6%-25%) | .55 |
| Outcome . | Iron overload defined as LIC >1.8 mg/g . | P . | Iron overload defined as LIC >5 mg/g . | P . | ||
|---|---|---|---|---|---|---|
| No iron overload, Prob (95% CI) . | Iron overload, Prob (95% CI) . | No iron overload, Prob (95% CI) . | Iron overload, Prob (95% CI) . | |||
| N | 28 | 60 | 65 | 23 | ||
| Overall survival, 1 y | 82% (62-92) | 72% (58-81) | .33 | 74% (61-83) | 78% (55-90) | .68 |
| NRM, 1 y* | 14% (2%-27%) | 13% (5%-22%) | .86 | 14% (5%-22%) | 13% (0%-26%) | .95 |
| Relapse, 1 y* | 21% (6%-73%) | 23% (13%-34%) | .92 | 22% (9%-36%) | 23% (12%-35%) | .91 |
| Composite end point, 1 y*† | 71% (51%-91%) | 80% (65%-95%) | .44 | 72% (53%-91%) | 81% (55%-97%) | .94 |
| Serious infections, 1 y* | 64% (43%-85%) | 73% (59%-88%) | .35 | 69% (55%-83%) | 74% (51%-97%) | .53 |
| Bacterial infections, 1 y* | 11% (0%-22%) | 13% (5%-22%) | .72 | 12% (4%-20%) | 13% (0%-27%) | .98 |
| Viral infections, 1 y* | 57% (37%-77%) | 68% (54%-83%) | .27 | 63% (49%-77%) | 70% (46%-93%) | .48 |
| Fungal infections, 1 y* | 7% (0%-17%) | 12% (4%-20%) | .49 | 12% (4%-20%) | 4% (0%-12%) | .28 |
| Respiratory failure, 1 y* | 11% (0%-22%) | 18% (9%-27%) | .38 | 17% (8%-26%) | 13% (1%-26%) | .64 |
| Cardiac failure, 1 y* | 0% | 8% (1%-15%) | .13 | 6% (1%-12%) | 9% (0%-20%) | .53 |
| Renal failure, 1 y* | 7% (0%-16%) | 10% (3%-17%) | .66 | 9% (2%-16%) | 9% (0%-20%) | .92 |
| Hepatic VOD, 1 y* | 4% (1%-8%) | 0% | .32 | 2% (0%-5%) | 0% | .74 |
| Acute GVHD, 100 days* | 50% (30%-70%) | 33% (21%-45%) | .16 | 42% (29%-54%) | 30% (12%-49%) | .44 |
| Chronic GVHD, 1 y* | 21% (6%-37%) | 17% (7%-26%) | .72 | 22% (9%-36%) | 15% (6%-25%) | .55 |